Article Figures & Data
Figures
- FIGURE 1.
Examples of different activity distributions after 177Lu-pentixather in patients 2 and 7 (P2 and P7, respectively), with multiple myeloma, and patient 15 (P15), with pre-B acute lymphoblastic leukemia. Although uptake in single kidney of patient 7 was 5%, sum of uptakes in both kidneys of patient 15 was only 1.1%. In contrast, retention was 3-fold higher in bone marrow and 11-fold higher in spleen of patient 15. p.i. = after injection.
- FIGURE 2.
Regions of interest used to derive time functions of activity retention in whole body (black), red bone marrow (red), liver (green), right kidney (purple solid circles), left kidney (purple open circles), and spleen (blue) in patient 3 with respective fit functions. Scintigram shows posterior whole-body image 24 h after 197 MBq of 177Lu-pentixather. Gray symbols with fit function represent activity retention per liter of whole blood.
Tables
Previous treatment Patient no. Sex Age (y) Weight (kg) Height (cm) eGFR Disease Since (mo) C R Auto Allo 1 M 61 60 158 99 MM 18 x 1 2 F 66 64 163 100 MM 54 x 3 3 F 53 74 165 54 MM 123 x 3 4 M 65 93 192 46 MM 101 x 2 5 M 74 60 173 54 MM 22 x x 2 6 M 71 80 175 79 MM 77 x x 2 7 F 66 60 166 40 MM 138 x x 1 8 F 57 104 157 96 MM 49 x x 1 9 M 59 77 172 50 MM 23 x x 2 10 M 46 70 183 92 AML 7 x 1 11 M 60 78 182 82 AML 19 x 1 12 F 54 62 168 67 AML 27 x 1 13 F 64 80 163 85 DLBCL 42 x 1 14 F 59 68 172 20 DLBCL 32 x x 1 15 F 75 75 168 59 pre-B ALL 15 x 16 F 50 78 172 54 TCL 21 x 1 17 F 55 64 160 96 ACC 46 x x 18 M 55 90 175 92 ACC 14 x x 19 F 40 52 163 n/a Thymoma 37 x x eGFR = Chronic Kidney Disease Epidemiology Collaboration glomerular filtrate rate estimate in mL/min per 1.73 m2; C = chemo; R = irradiation; auto = autologous stem cells; allo = allogeneic stem cells; MM = multiple myeloma; AML = acute myeloid leukemia; DLBCL = diffuse large B-cell lymphoma; pre-B ALL = pre-B acute lymphoblastic leukemia; TCL = T-cell leukemia; ACC = adrenocortical carcinoma; n/a = not available.
- TABLE 2.
177Lu-Pentixather Time-Integrated Activity Coefficients in Whole Body, Organs, Tumorous Lesions, Red Marrow, and Blood, as Well as Tissue-Absorbed Doses per Administered Activity in Organs and Lesions
WB Kidneys Liver Spleen Red marrow Lesion Blood Patient no. ã (h) ã (h) D/A (Gy/GBq) ã (h) D/A (Gy/GBq) ã (h) D/A (Gy/GBq) ã (h) D/A (Gy/GBq) D/A (Gy/GBq) ã (h/L) 1 51.6 4.39 1.01 3.8 0.39 2.06 0.58 4.0 0.14 2.2 0.21 2 56.1 2.42 0.71 14.4 0.82 2.49 1.55 8.1 0.37 6.9 0.58 3 55.3 4.85 2.10 15.2 0.93 1.27 0.72 14.3 0.66 0.48 4 97.6 4.61 1.48 16.2 0.80 2.03 0.70 13.7 0.48 0.28 5 87.7 1.92 0.87 12.2 0.91 3.71 1.59 16.8 0.59 1.7 6 62.1 1.74 0.50 11.7 0.62 0.63 0.34 11.8 0.41 3.1 7 111.0 6.25 3.47 15.0 1.17 1.34 1.12 10.6 0.48 8 61.6 5.28 1.21 10.0 0.39 0.90 0.38 9.4 0.43 9 111.6 4.76 1.12 13.2 0.67 1.18 0.47 13.6 0.47 10 50.5 4.51 0.90 9.0 0.43 2.47 0.40 9.9 0.35 0.32 11 55.9 4.34 1.14 8.0 0.42 1.43 0.48 9.1 0.32 0.34 12 77.8 2.03 0.79 13.9 0.71 3.46 0.75 21.3 0.97 1.1 13 114.9 7.87 0.91 21.9 0.67 2.65 0.35 22.8 1.04 2.1 14 83.6 1.63 0.59 16.7 0.88 11.5 1.20 16.4 0.75 15 140.9 1.04 0.38 15.5 0.71 14.0 2.26 51.0 2.33 16 108.8 3.22 1.07 14.1 0.50 6.51 1.03 12.2 0.56 1.6 0.28 17 73.6 1.93 0.52 20.1 0.92 2.38 0.56 5.5 0.25 2.3 0.28 18 51.6 3.47 0.67 12.0 0.41 3.30 0.42 4.0 0.14 1.1 0.32 19 48.0 5.23 1.96 9.4 0.81 0.44 0.48 8.5 0.39 0.7 0.44 P 0.03 0.31 <0.01 0.95 0.21 <0.01 < 0.01 <0.01 <0.01 < 0.01 0.23 Minimum 48.0 1.04 0.38 3.7 0.39 0.44 0.34 4.0 0.14 0.7 0.21 First quartile 55.6 1.98 0.70 10.9 0.47 1.30 0.45 8.8 0.36 1.2 0.28 Median 73.6 4.34 0.91 13.9 0.71 2.38 0.58 11.8 0.47 1.9 0.32 Third quartile 103.2 4.80 1.18 15.4 0.85 3.38 1.08 15.4 0.62 2.3 0.42 Maximum 140.9 7.87 3.47 21.9 1.17 14.0 2.26 51.0 2.33 6.9 0.58 Mean 79.0 3.77 1.13 13.3 0.69 3.36 0.81 13.8 0.59 2.3 0.35 SD 27.9 1.82 0.73 4.2 0.22 3.61 0.52 10.4 0.49 1.8 0.11 WB = whole body; ã = time-integrated activity coefficient; D/A = tissue-absorbed doses per administered activity.
P values are from Shapiro–Wilk test of normality.
- TABLE 3.
90Y-Pentixather Time-Integrated Activity Coefficients in Whole Body, Organs, Tumorous Lesions, Red Marrow, and Blood, as Well as Tissue-Absorbed Doses per Administered Activity in Organs and Lesions (Recalculated from Kinetics Measured with 177Lu-Pentixather)
WB Kidneys Liver Spleen Red marrow Lesion Blood Patient no. ã (h) ã (h) D/A (Gy/GBq) ã (h) D/A (Gy/GBq) ã (h) D/A (Gy/GBq) ã (h) D/A (Gy/GBq) D/A (Gy/GBq) ã (h/L) 1 31.5 3.03 3.91 1.9 1.18 1.05 1.66 2.3 0.34 6.1 0.19 2 33.6 1.90 3.16 5.8 1.91 0.95 3.30 4.0 0.77 18.2 0.48 3 35.1 2.95 7.32 6.0 2.12 0.53 1.70 7.4 1.42 0.42 4 51.6 2.97 5.36 6.3 1.80 0.82 1.58 6.0 0.88 0.28 5 50.8 1.22 3.10 6.1 2.65 1.26 3.04 8.4 1.23 4.1 6 40.1 1.31 2.12 5.2 1.61 0.40 1.20 7.4 1.09 9.2 7 54.2 3.87 12.2 6.6 2.97 0.69 3.22 6.5 1.25 8 34.5 3.74 4.85 5.4 1.22 0.45 1.07 5.1 0.98 9 58.5 3.22 4.29 6.1 1.77 0.67 1.51 7.2 1.06 10 32.8 3.32 3.75 4.6 1.29 1.07 0.97 4.9 0.72 0.28 11 35.7 2.83 4.21 3.8 1.16 0.76 1.42 4.7 0.69 0.30 12 47.2 1.41 3.16 5.4 1.61 2.06 2.51 10.1 1.94 3.4 13 59.3 4.89 3.21 8.5 1.51 1.42 1.05 8.9 1.72 4.7 14 49.6 1.04 2.15 7.6 2.32 6.63 3.85 9.6 1.85 15 67.7 0.71 1.48 6.0 1.57 7.40 6.69 23.2 4.45 16 63.8 2.38 4.50 7.8 1.59 3.04 2.70 7.1 1.36 4.2 0.26 17 41.1 1.39 2.15 8.7 2.31 1.41 1.88 3.1 0.59 5.4 0.44 18 34.5 2.47 2.67 5.7 1.14 1.58 1.13 1.8 0.27 3.6 0.28 19 29.9 3.53 7.52 3.6 1.80 0.25 1.53 3.5 0.68 1.5 0.40 P 0.08 0.53 <0.01 0.55 0.13 <0.01 <0.01 <0.01 <0.01 <0.01 0.31 Minimum 29.9 0.71 1.48 2.0 1.14 0.25 0.97 1.83 0.27 1.5 0.19 First quartile 34.5 1.40 2.88 5.3 1.40 0.68 1.31 4.35 0.71 3.7 0.28 Median 41.1 2.83 3.75 6.0 1.61 1.05 1.66 6.50 1.06 4.5 0.29 Third quartile 52.9 3.27 4.67 6.4 2.02 1.50 2.87 7.88 1.39 5.9 0.41 Maximum 67.7 4.89 12.2 8.7 2.97 7.40 6.69 23.2 4.45 18.2 0.48 Mean 44.8 2.54 4.27 5.9 1.77 1.71 2.21 6.90 1.22 6.0 0.33 SD 12.0 1.14 2.52 1.7 0.51 1.99 1.39 4.61 0.91 4.7 0.10 WB = whole body; ã = time-integrated activity coefficient; D/A = tissue-absorbed doses per administered activity.
P values are from Shapiro–Wilk test of normality.
Supplemental Data
Files in this Data Supplement:
In this issue
Jump to section
Related Articles
Cited By...
- Rethinking Dosimetry: A European Perspective
- Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cells
- CXCR4-Directed Imaging and Endoradiotherapy in Desmoplastic Small Round Cell Tumors
- Theranostics in Hematooncology
- Detecting CXCR4 Expression in Meningioma on 68Ga-Pentixafor PET/MRI
- C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma